Clinical trials›Gastric Cancer›Lifestyle›Trial details
UNKNOWNObservation Study

The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments

For Condition: Gastric CancerFor Condition: Neoadjuvant ChemotherapyFor Condition: Neoadjuvant ChemoradiotherapyFor Condition: Systemic Inflammatory Response Syndrome (SIRS)For Condition: Nutrition Aspect of Cancer

ID: NCT03493880

Horizon Patient Guidance Summary

Our intelligence engine has synthesized this trial record to answer your most important questions in clear, simple terms:

How it’s taken
Diet & Lifestyle / Therapy Care
Expected Availability Horizon
General pipeline timeline
StageGeneral evaluation study exploring treatment methods.
EligibleThis study is looking exclusively for patients diagnosed with the condition.
About This Clinical Trial

Based on multiple studies, the immune (systemic inflammation) and nutrition index were correlated with short- and long-term prognosis for gastric cancer. With the increasing application of preoperative treatments (chemotherapy and chemoradiotherapy), the issues concerning how are the immuno-nutrition index be altered under the effects of perioperative treatments and what are the clinical values of these index should be clarified.

Read Full Scientific Objectives & Methods

The immune (systemic inflammation) index includes: NLR (Neutrophil-to-Lymphocyte Ratio); PLR (Platelet-to-Lymphocyte Ratio); SII (Systemic Immune-Inflammation Index); GPS (Glasgow Prognostic Score); mGPS (modified Glasgow Prognostic Score); PI (Prognostic Index); The nutrition index includes: NRS2002; PNI (Prognostic Nutrition Index);

Study Timeline & Quick Facts
Trial Status
Status Unknown
Total Target Enrollment
600 patients (Estimated)
Study Start Date
2015-09-01
Est. Primary Completion
2020-09-01
Tested Drugs & Treatment Groups

Treatment Arms Description

ARM GROUPnaCT

Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemotherapy.

ARM GROUPnaCRT

Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemoradiotherapy.

Can I Join This Study?
Suitable For
Everyone welcome
Ages Welcome
No age restriction
Full Criteria Checklist
Who Can Join
  • Histologically confirmed adenocarcinoma
  • Received neoadjuvant (preoperative) chemotherapy or chemoradiotherapy
  • Diagnosed clinical advanced gastric cancer or esophagogastric cancer
Who Cannot Join
  • Lack of immuno-nutrition data
What is this Study Measuring?

Primary Outcome Measures

  • Pathological response — Time Frame: One month after surgery

    Pathological response

View Secondary Outcome Measures (4)
  • 3-years overall survival — Time Frame: Three years after surgery

    3-years overall survival

  • 3-years disease-free survival — Time Frame: Three years after surgery

    3-years disease-free survival

  • Postoperative morbidity — Time Frame: One month after surgery

    Postoperative morbidity

  • yp TNM Stage — Time Frame: One month after surgery

    yp TNM Stage

Where to Participate

This trial is recruiting at 1 study facilities worldwide. Click below to see if there is a clinic or hospital in your area:

Show All 1 Facilities & Contact Sites
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
Status: Open
Sponsoring Teams & Contacts
Lead Sponsoring Institution
Peking University
Primary Research Contact
Shuangxi Li, M.D., Ph.D.
Clinical Trial Application Copilot

Want to apply or inquire about joining this study? Fill out this simple questionnaire, and our assistant will instantly generate a professional email draft you can copy and send to the central contact coordinator listed above!

Generated Professional Email Draft:
View Official Medical/Scientific Title

The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments: Observational Cohort Study